Can you take Arava with Asparaginase escherichia coli?

asparaginase Escherichia coli has a major potential interaction with Bleeding Disorder.

Impaired synthesis of fibrinogen and decreased serum levels of clotting factors have been reported in patients in asparaginase therapy. Bleeding has been observed in patients with coagulation disorders. Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, hematuria, or melena. Therapy with asparaginase should be administered cautiously to patients with coagulation disorders. The use of asparaginase is contraindicated in patients with serious bleeding or history of serious hemorrhagic events with prior to asparaginase therapy.

The leflunomide in Arava has a major potential interaction with Bone Marrow Depression/Low Blood Counts.

Pancytopenia, agranulocytosis and thrombocytopenia have been reported in patients receiving leflunomide. Leflunomide is an immunomodulatory agent with antiproliferative activity. The use of leflunomide is not recommended in patients with severe immunodeficiency, bone marrow dysplasia, or severe, uncontrolled infections because of the theoretical potential for immunosuppression. Care should be taken when using this agent in patients with a prior history of a significant hematologic abnormality. It is recommended to monitor blood levels at baseline and regularly during the course of therapy. If evidence of bone marrow suppression occurs, stop treatment and institute appropriate measures according to clinical guidelines.

asparaginase Escherichia coli has a moderate potential interaction with Bone Marrow Depression/Low Blood Counts.

Transient myelosuppression has been observed during asparaginase therapy, however its myelosuppressive effect has not been well characterized. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended. Therapy with asparaginase should be administered cautiously in patients with severe bone marrow suppression.

asparaginase Escherichia coli has a major potential interaction with Coagulation Defects and Disorders.

Impaired synthesis of fibrinogen and decreased serum levels of clotting factors have been reported in patients in asparaginase therapy. Bleeding has been observed in patients with coagulation disorders. Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, hematuria, or melena. Therapy with asparaginase should be administered cautiously to patients with coagulation disorders. The use of asparaginase is contraindicated in patients with serious bleeding or history of serious hemorrhagic events with prior to asparaginase therapy.

The leflunomide in Arava has a major potential interaction with Diabetes Mellitus.

Peripheral neuropathy has been reported during leflunomide therapy. Patients older than 60 years, patients taking concomitant neurotoxic medications, and diabetics may be at an increased risk for peripheral neuropathy. Therapy with leflunomide should be administered cautiously in these patients. Patients should be monitored for symptoms of neuropathy and if confirmed, consider discontinuing therapy and taking measures according to clinical practice.

asparaginase Escherichia coli has a moderate potential interaction with Diabetes Mellitus.

Glucose intolerance has been reported in patients receiving asparaginase. In some cases glucose intolerance may be irreversible. Monitor glucose levels in patients at baseline and periodically during treatment. Administer insulin therapy as necessary in patients with hyperglycemia. Therapy with asparaginase should be administered cautiously in patients with diabetes mellitus.

The leflunomide in Arava has a moderate potential interaction with High Blood Pressure.

Hypertension was reported as an adverse reaction in patients on leflunomide. Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.

The leflunomide in Arava has a major potential interaction with Immunodeficiency.

Pancytopenia, agranulocytosis and thrombocytopenia have been reported in patients receiving leflunomide. Leflunomide is an immunomodulatory agent with antiproliferative activity. The use of leflunomide is not recommended in patients with severe immunodeficiency, bone marrow dysplasia, or severe, uncontrolled infections because of the theoretical potential for immunosuppression. Care should be taken when using this agent in patients with a prior history of a significant hematologic abnormality. It is recommended to monitor blood levels at baseline and regularly during the course of therapy. If evidence of bone marrow suppression occurs, stop treatment and institute appropriate measures according to clinical guidelines.

The leflunomide in Arava has a major potential interaction with Infection.

Pancytopenia, agranulocytosis and thrombocytopenia have been reported in patients receiving leflunomide. Leflunomide is an immunomodulatory agent with antiproliferative activity. The use of leflunomide is not recommended in patients with severe immunodeficiency, bone marrow dysplasia, or severe, uncontrolled infections because of the theoretical potential for immunosuppression. Care should be taken when using this agent in patients with a prior history of a significant hematologic abnormality. It is recommended to monitor blood levels at baseline and regularly during the course of therapy. If evidence of bone marrow suppression occurs, stop treatment and institute appropriate measures according to clinical guidelines.

The leflunomide in Arava has a major potential interaction with Liver Disease.

Severe liver injury, including fatal liver failure, has been reported in patients treated with leflunomide. Leflunomide is contraindicated in patients with severe hepatic impairment. Leflunomide has been commonly associated with elevations in liver enzymes, primarily ALT and AST. Marked elevations occurred infrequently and reversed with dose reduction or discontinuation of treatment. Leflunomide also must be metabolized by the liver into the active compound which is responsible for the in vivo activity. Therapy with leflunomide is not recommended in patients with preexisting liver disease. Dosage adjustment or discontinuation is recommended for patients experiencing liver enzyme elevations while on leflunomide.

asparaginase Escherichia coli has a moderate potential interaction with Liver Disease.

Reversible liver abnormalities such as elevated liver transaminase and bilirubin levels and decreased albumin synthesis have been reported during asparaginase therapy. Fatty changes in the liver have been noted. Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia. Therapy with asparaginase should be administered cautiously to patients with or predisposed to compromised hepatic function. Clinical monitoring of hepatic function is recommended.

asparaginase Escherichia coli has a major potential interaction with Pancreatitis.

The use of asparaginase is contraindicated in patients with pancreatitis or a history of pancreatitis. Pegaspargase can cause decreased insulin synthesis or may cause inflammation and/or necrosis of cells of the pancreas. Fulminant and fatal pancreatitis has occurred. Clinical monitoring of pancreatic function, including serum amylase levels, is recommended.

The leflunomide in Arava has a major potential interaction with Peripheral Neuropathy.

Peripheral neuropathy has been reported during leflunomide therapy. Patients older than 60 years, patients taking concomitant neurotoxic medications, and diabetics may be at an increased risk for peripheral neuropathy. Therapy with leflunomide should be administered cautiously in these patients. Patients should be monitored for symptoms of neuropathy and if confirmed, consider discontinuing therapy and taking measures according to clinical practice.

asparaginase Escherichia coli has a minor potential interaction with Psychosis.

Reversible CNS symptoms, varying from mild to severe, such as depression, confusion, agitation, or hallucinations have been reported. Patients with existing or predisposition to psychoses or emotional disorders may be at increase risk for CNS symptoms associated with asparaginase therapy. Clinical monitoring of mental status is recommended.

The leflunomide in Arava has a major potential interaction with Pulmonary Impairment.

The use of leflunomide has been associated with pulmonary toxicity. Serious cases of interstitial lung disease (ILD), and worsening of preexisting interstitial lung disease have been reported. Caution is recommended when using this agent in patients with a history of ILD or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as cough and dyspnea, with or without associated fever. If ILD is confirmed, consider discontinuing therapy and institute appropriate measures according to clinical guidelines.

The leflunomide in Arava has a major potential interaction with Renal Dysfunction.

The active metabolite of leflunomide is elevated in the plasma of patients with renal impairment. Therapy with leflunomide should be administered cautiously in patients with renal insufficiency.

The leflunomide in Arava has a major potential interaction with Tuberculosis, Active.

Patients should be evaluated for active and latent tuberculosis (TB) infection prior to leflunomide treatment. Leflunomide has not been studied in patients with a positive tuberculosis screen, and the safety of leflunomide in individuals with latent tuberculosis infection is unknown. Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with leflunomide and monitored carefully during leflunomide treatment for possible reactivation of the infection.

The leflunomide in Arava has a major potential interaction with Tuberculosis, Latent.

Patients should be evaluated for active and latent tuberculosis (TB) infection prior to leflunomide treatment. Leflunomide has not been studied in patients with a positive tuberculosis screen, and the safety of leflunomide in individuals with latent tuberculosis infection is unknown. Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with leflunomide and monitored carefully during leflunomide treatment for possible reactivation of the infection.